Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation and Summary of Significant Accounting Policies (Tables)

v3.22.2.2
Basis of Presentation and Summary of Significant Accounting Policies (Tables)
3 Months Ended
Sep. 30, 2022
Protein Sciences [Member]  
Notes Tables  
Schedule of restructuring charges The related first quarter of fiscal 2023 restructuring charges were recorded in the income statement as follows (in thousands):

Employee

Asset

    

severance

    

related and other

    

Total

Selling, general and administrative

$

1,328

$

842

$

2,170

Restructuring actions, including cash and non-cash impacts, are as follows (in thousands):

Employee

Asset

    

severance

    

related and other

    

Total

Expense incurred in the first quarter of 2023

$

1,328

$

842

$

2,170

Cash payments

(420)

(431)

(851)

Adjustments

(72)

(72)

Accrued restructuring actions balances as of September 30, 2022

$

908

339

1,247

Diagnostics and Genomics [Member]  
Notes Tables  
Schedule of restructuring charges Total restructuring charges for the closure of the Exosome Diagnostics Germany facility for the year ended June 30, 2022 were recorded within operating income on the income statement as follows (in thousands):

:

Employee

Asset

    

severance

    

Impairment and other

    

Total

Selling, general and administrative

$

649

$

750

$

1,399

Employee

Asset

    

severance

    

Impairment and other

    

Total

Expense incurred in the first quarter of 2022

$

639

$

546

$

1,185

Incremental expense incurred during fiscal 2022

242

242

Cash payments

(589)

(554)

(1,143)

Adjustments(1)

(50)

(234)

(284)

Accrued restructuring actions balances as of June 30, 2022

$

(1)Adjustments include refinements to our estimated close down costs as well as the impacts from foreign currency exchange.